Anand Patel, Assistant Professor and Director of the Inpatient Leukemia Service at the University of Chicago, shared on X/Twitter:
“Does JAK2 VAF reduction in PV/ET impact outcomes in rux-treated patients?
Pic 1 – MF-free survival in patients treated with rux on PV or ET trials:
Pic 2 – events on MAJIC-PV trial.”
Source: Anand Patel/X